MX2020003746A - Vectores adenovirales con dos casetes de expresion. - Google Patents

Vectores adenovirales con dos casetes de expresion.

Info

Publication number
MX2020003746A
MX2020003746A MX2020003746A MX2020003746A MX2020003746A MX 2020003746 A MX2020003746 A MX 2020003746A MX 2020003746 A MX2020003746 A MX 2020003746A MX 2020003746 A MX2020003746 A MX 2020003746A MX 2020003746 A MX2020003746 A MX 2020003746A
Authority
MX
Mexico
Prior art keywords
simian adenoviral
expression cassettes
adenoviral vectors
adenoviral vector
simian
Prior art date
Application number
MX2020003746A
Other languages
English (en)
Spanish (es)
Inventor
Stefano Colloca
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of MX2020003746A publication Critical patent/MX2020003746A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/235Adenoviridae
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10334Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10342Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16111Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16121Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/20011Rhabdoviridae
    • C12N2760/20111Lyssavirus, e.g. rabies virus
    • C12N2760/20134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/48Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
MX2020003746A 2017-10-16 2018-10-16 Vectores adenovirales con dos casetes de expresion. MX2020003746A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762572944P 2017-10-16 2017-10-16
PCT/EP2018/078210 WO2019076880A1 (en) 2017-10-16 2018-10-16 SIMIENS ADENOVIRAL VECTORS COMPRISING TWO EXPRESSION CASSETTES

Publications (1)

Publication Number Publication Date
MX2020003746A true MX2020003746A (es) 2020-11-06

Family

ID=63896161

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003746A MX2020003746A (es) 2017-10-16 2018-10-16 Vectores adenovirales con dos casetes de expresion.

Country Status (9)

Country Link
US (2) US20200299651A1 (cg-RX-API-DMAC7.html)
EP (1) EP3697918B1 (cg-RX-API-DMAC7.html)
JP (1) JP2021500880A (cg-RX-API-DMAC7.html)
CN (1) CN111479926A (cg-RX-API-DMAC7.html)
AR (1) AR114989A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020007413A2 (cg-RX-API-DMAC7.html)
CA (1) CA3084346A1 (cg-RX-API-DMAC7.html)
MX (1) MX2020003746A (cg-RX-API-DMAC7.html)
WO (1) WO2019076880A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7454645B2 (ja) 2019-07-16 2024-03-22 ギリアード サイエンシーズ, インコーポレイテッド Hivワクチン並びにその作製方法及び使用方法
IL315295A (en) 2019-09-30 2024-10-01 Gilead Sciences Inc Hbv vaccines and methods treating hbv
TW202144570A (zh) * 2020-01-28 2021-12-01 美商科達金尼克斯有限公司 去最佳化(DEOPTIMIZED)SARS-CoV-2及其方法及用途
CA3259040A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. HIV Immunogenic Polypeptides and Vaccines and Their Uses

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040136963A1 (en) * 2001-06-22 2004-07-15 The Trustees Of The University Of Pennsylvania Simian adenovirus vectors and methods of use
CA2562893A1 (en) * 2004-04-28 2005-11-10 The Trustees Of The University Of Pennsylvania Polyvalent viral vectors and a system for production thereof
WO2008095027A2 (en) 2007-01-30 2008-08-07 Cedars-Sinai Medical Center Adenoviral vector comprising herpes simplex virus type 1 thymidine kinase and a transgene for increasing the expression of the transgene
EP2181121A4 (en) 2007-03-21 2012-07-11 Id Biomedical Corp Quebec CHIMÄRE ANTIGENE
CA2738654C (en) 2008-09-27 2019-02-26 Witricity Corporation Wireless energy transfer systems
EP3385387B1 (en) 2009-02-02 2021-08-25 GlaxoSmithKline Biologicals SA Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
WO2012021730A2 (en) * 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
WO2012089231A1 (en) 2010-12-30 2012-07-05 Okairòs Ag Paramyxovirus vaccines
CN103492574B (zh) 2011-02-22 2015-12-09 加州理工学院 使用腺相关病毒(aav)载体递送蛋白
EP2764011B1 (en) * 2011-10-05 2021-04-07 GenVec, Inc. Adenoviral vector-based respiratory syncytial virus (rsv) vaccine
MX384992B (es) * 2014-06-13 2025-03-14 Glaxosmithkline Biologicals Sa Combinaciones inmunógenas.
BE1024420B1 (fr) 2015-06-12 2018-02-19 Glaxosmithkline Biologicals Sa Polynucleotides et polypeptides d'adenovirus
GB201513176D0 (en) * 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
BE1024774B1 (fr) 2016-09-29 2018-07-02 Glaxosmithkline Biologicals Sa Compositions et procedes de traitement

Also Published As

Publication number Publication date
JP2021500880A (ja) 2021-01-14
WO2019076880A1 (en) 2019-04-25
AR114989A1 (es) 2020-11-18
EP3697918A1 (en) 2020-08-26
US20240093161A1 (en) 2024-03-21
US12180512B2 (en) 2024-12-31
EP3697918B1 (en) 2025-11-26
US20200299651A1 (en) 2020-09-24
CA3084346A1 (en) 2019-04-25
BR112020007413A2 (pt) 2020-12-08
CN111479926A (zh) 2020-07-31

Similar Documents

Publication Publication Date Title
MX2020003746A (es) Vectores adenovirales con dos casetes de expresion.
USD752583S1 (en) Watch body
CL2020001064A1 (es) Dispositivo de suministro de aerosol.
CL2018000587A1 (es) Adenovirus oncolítico que codifica una proteína b7 (divisional de sol. n° 2731-2017)
AR118928A1 (es) Métodos de redosificación de vectores de terapia génica
CL2019000392A1 (es) Métodos para detectar aav.
CO2019000395A2 (es) Genes de mini–distrofina optimizados y casetes de expresión y su uso
CL2020000810A1 (es) Proteínas de fusión que comprenden enzimas de terapia de reemplazo de enzimas.
CO2021017650A2 (es) Vectores víricos y uso de los mismos en terapias celulares adoptivas
MX2018015540A (es) Promotor bidireccional potente y equilibrado.
MX2017002900A (es) Terapia genica de globina para el tratamiento de hemoglobinopatias.
USD709932S1 (en) Log splitter wedge housing
BR112017006884B8 (pt) Estator de turbomáquina de aeronave e turbomáquina de aeronave
MX2021006408A (es) Terapia de combinacion de radioinmunoconjugados con inhibidores de da?os y reparaciones del adn.
MX389312B (es) Promotores para mejorar la expresion en poxvirus.
CO2017011046A2 (es) Prenda absorbente con buen ajuste
CO2019004474A2 (es) Remolcador equipado con unidades de propulsión acimutales
MX2021003830A (es) Uso terapéutico del glucagón y combinación que incluye el mismo.
MX2018000845A (es) Vector vírico orf recombinante.
MX2018014789A (es) Fabricacion de calzado con una cara superior de patron plano incrustada.
AR113134A1 (es) Arni variante
MX2019008922A (es) Mutantes de la caja tata y de la caja caat selectivas de tumor.
DOP2016000220A (es) PROTEÍNAS DE FUSIÓN TATk-CDKL5, COMPOSICIONES, FORMULACIONES Y USO DE ESTAS.
MX2020003748A (es) Vectores adenovirales con dos casetes de expresion que codifican proteinas antigenicas del vsr o fragmentos de las mismas.
BR112016015839A2 (pt) Bomba vertical contendo cabeçote de descarga com elemento flexível